XBiotech/$XBIT
13:30
21:10
04:45
12:25
20:00
1D1W1MYTD1Y5YMAX
About XBiotech
XBiotech Inc is a biopharmaceutical company that discovers and develops True Human monoclonal antibodies derived from human donors to replicate the human immune response in the treatment of various diseases. It has developed a pipeline of product candidates using True Human antibodies targeting both inflammatory and infectious diseases. The company's developement pipeline comprises: Natrunix, an antibody targeting IL-1a in oncology (pancreatic cancer), a clinical stage therapeutic for Methicillin Resistant Staphylococcus aureus (MRSA), and several pre-clinical stage therapeutics, including: an oral delivery antibody therapeutic for colon infection by C. difficile; an injectable therapy for varicella zoster (adult chicken pox), the causative agent for shingles; and an influenza therapy.
Ticker
$XBIT
Sector
Primary listing
Employees
87
Headquarters
Website
XBiotech Metrics
BasicAdvanced
$72m
-
-$1.32
0.86
-
Price and volume
Market cap
$72m
Beta
0.86
52-week high
$3.61
52-week low
$2.09
Average daily volume
28k
Financial strength
Current ratio
39.029
Quick ratio
38.6
Profitability
EBITDA (TTM)
-46.833
Effective tax rate (TTM)
-0.64%
Management effectiveness
Return on assets (TTM)
-18.81%
Return on equity (TTM)
-25.93%
Valuation
Price to book
0.54
Price to tangible book (TTM)
0.54
Price to free cash flow (TTM)
-1.706
Free cash flow yield (TTM)
-58.63%
Free cash flow per share (TTM)
-1.39
Growth
Earnings per share change (TTM)
1.84%
3-year earnings per share growth (CAGR)
8.58%
10-year earnings per share growth (CAGR)
0.61%
XBiotech Financial Performance
Revenues and expenses
XBiotech Earnings Performance
Company profitability
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs